Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dupixent Approved For Severe Asthma With Broader Label Than Other Biologics

Executive Summary

The US FDA cleared Sanofi/Regeneron's IL-4/IL-13 inhibitor for moderate-to-severe asthma in patients with an eosinophilic phenotype or with oral corticosteroid-dependent asthma, a broader label than AstraZeneca's Fasenra, GSK's Nucala and Teva's Cinqair.

Advertisement

Related Content

Dermira’s Lebrikizumab Data Set Up Atopic Dermatitis Showdown With Dupixent
Sanofi Prioritizes Cancer And Rare Diseases In Pipeline Shake-Up
ICER On Asthma Biologics: 50%-79% Price Discounts Needed To Meet Value Assessment Metrics
Sanofi's Vaccines Performance Helps Offset Diabetes Decline
Pharma Q3 Preview: Amgen, Allergan, Pfizer, GSK And Sanofi
Next Up For AstraZeneca: Building Out In Renal Disease
Not To Be Sniffed At: Dupixent Success In Rhinosinusitis Could Open Up Large Additional Market
Severe Asthma Market Snapshot: A Competitive Therapy Area That Will Test Payers' Influence
AZ Looks To Lead Severe Asthma Market After US Fasenra OK
Sanofi, Regeneron Setting 'New Paradigm' With Dupixent Pricing In US?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124031

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel